Drug development
The development of biotechnologically produced drugs has made it possible to treat diseases at their cause, to do this more efficiently and with fewer side effects, or even to cure diseases. This is the focus of five biotechnology companies on Campus Berlin-Buch.
The spectrum of their drug development includes highly specific cancer antibodies (Glycotope GmbH), novel treatments targeting the cause of heart failure (Berlin Cures GmbH) or atrial fibrillation (OMEICOS Therapeutics GmbH), extremely effective antibiotics (MerLion Pharmaceuticals) and RNAi-based therapeutics for systemic cancers that can selectively regulate disease-related genes (Silence Therapeutics). Here, T-Knife, a spin-off from the Charité and the Max Delbrück Center, is developing one of the first T cell receptor gene therapies in Germany.
News innovation
"Drivers for Germany's Future Sustainability"
The UNIPRENEURS Initiative has recognized the entrepreneurial spirit of 20 professors, among them ECRC researcher Simone Spuler. As a co-founder of the startup MyoPax, she is pioneering stem cell tech...
more ...Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023.
more ...Biosynth Expands Capabilities with Acquisition of celares, Experts in Bioconjugation and Specialty Polymers
Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired celares, a leader in the development and manufacture of conjugate vaccine...
more ...Events Campus
09.10.2023, 09:00
Explore Precision Medicine Event im Futurium
Das Gläserne Labor beteiligt sich am 9. Oktober 2023 am Explore Precision Medicine Event im Futurium mit Workshops und Präsentationen.
more ...
